Compare Goodyear Tire & Rubber Co (GT) vs Moderna, Inc. (MRNA) Price & Performance

The Goodyear Tire & Rubber Company (GT) trades at $5.98, down 0.83% on the day, reflecting ongoing pressure from declining revenue and a significant net loss of $1.72 billion in 2025. Technical indicators are bearish, with moving averages signaling a downtrend, while fundamentals show a low P/E of 4.69 and P/B of 0.62, suggesting potential undervaluation despite negative profitability metrics like a -14.37% net income margin. Recent Q2 2026 earnings showed a loss of $0.61 per share, beating expectations but highlighting volume challenges.

GT presents a high-risk opportunity with its cheap valuation offset by weak earnings and cash flow volatility. Analyst sentiment is mixed, with 34.62% buy ratings, but risks include persistent volume declines, high debt, and competitive pressures. The stock's outlook hinges on operational improvements and market stabilization, making it speculative for value investors.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.